CH686870A5 - Solution de perfusion, de conservation et de reperfusion d'organes. - Google Patents
Solution de perfusion, de conservation et de reperfusion d'organes. Download PDFInfo
- Publication number
- CH686870A5 CH686870A5 CH02760/93A CH276093A CH686870A5 CH 686870 A5 CH686870 A5 CH 686870A5 CH 02760/93 A CH02760/93 A CH 02760/93A CH 276093 A CH276093 A CH 276093A CH 686870 A5 CH686870 A5 CH 686870A5
- Authority
- CH
- Switzerland
- Prior art keywords
- glutathione
- solution
- reduced
- solution according
- mmol
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title description 15
- 230000010412 perfusion Effects 0.000 title description 9
- 238000004321 preservation Methods 0.000 title description 7
- 239000003978 infusion fluid Substances 0.000 title 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 62
- 108010024636 Glutathione Proteins 0.000 claims description 30
- 229960003180 glutathione Drugs 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 230000010410 reperfusion Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 9
- 229960004308 acetylcysteine Drugs 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229930195712 glutamate Natural products 0.000 claims description 6
- 229940099584 lactobionate Drugs 0.000 claims description 6
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 5
- GZFOMNDCXQBAAX-BQBZGAKWSA-N (2s)-2-amino-5-[[(2r)-1-[(2-methoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound COC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O GZFOMNDCXQBAAX-BQBZGAKWSA-N 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 150000003841 chloride salts Chemical class 0.000 claims description 3
- 229960000958 deferoxamine Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 48
- 150000003254 radicals Chemical class 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 239000008148 cardioplegic solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- -1 glutathione Chemical class 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000004078 waterproofing Methods 0.000 description 2
- 241000282465 Canis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical group [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940072417 peroxidase Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000036313 post-ischemic recovery Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94607392A | 1992-09-18 | 1992-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH686870A5 true CH686870A5 (fr) | 1996-07-31 |
Family
ID=25483919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH02760/93A CH686870A5 (fr) | 1992-09-18 | 1993-09-14 | Solution de perfusion, de conservation et de reperfusion d'organes. |
Country Status (9)
| Country | Link |
|---|---|
| AT (1) | AT407216B (de) |
| BE (1) | BE1007500A3 (de) |
| CA (1) | CA2106249C (de) |
| CH (1) | CH686870A5 (de) |
| DE (1) | DE4331711C2 (de) |
| ES (1) | ES2070089B1 (de) |
| FR (1) | FR2695827B1 (de) |
| GB (1) | GB2270614B (de) |
| IT (1) | IT1272638B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19527734A1 (de) * | 1995-07-28 | 1997-01-30 | Hubert Verhaag | Verfahren und Vorrichtung zur Konservierung von Geweben und Organen, insbesondere von Transplantationsgeweben und -organen |
| SE9601396D0 (sv) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 2 |
| US5880098A (en) * | 1996-04-12 | 1999-03-09 | Pharmacia & Upjohn Aktiebolag | Therapeutic treatment |
| DE19706111C2 (de) * | 1997-02-17 | 1999-02-18 | Fresenius Medical Care De Gmbh | Lösung zur Aufbewahrung von Organen |
| RU2140152C1 (ru) * | 1997-03-13 | 1999-10-27 | Иван Антонович Мазур | Консервирующий раствор "б-2" для трансплантатов |
| US5834178C1 (en) * | 1997-07-09 | 2002-04-23 | Univ Wayne State | Flush-storage solution for donor organs |
| CN1057192C (zh) * | 1997-09-10 | 2000-10-11 | 上海长征医院 | 一种配制多器官保存液的方法 |
| DE19834087C1 (de) * | 1998-07-29 | 2000-03-30 | Mirzaie Sedaposhteh Massoud | Wäßrige Konservierungslösung und Verfahren zur Aufbewahrung tierischen Gewebes |
| FR2785501B1 (fr) * | 1998-11-10 | 2001-01-05 | Centre Nat Rech Scient | Solution de perfusion et/ou de conservation et/ou de reperfusion lors de la transplantation d'organes |
| GB0028414D0 (en) | 2000-11-22 | 2001-01-03 | Univ Leeds | Flush preservation solution |
| US20060078872A1 (en) * | 2004-10-12 | 2006-04-13 | Atsushi Taguchi | Cell-preservation liquid |
| WO2007128866A2 (en) * | 2006-05-09 | 2007-11-15 | Novobion Oy | Novel chemical compositions |
| CA2910189A1 (en) * | 2013-04-24 | 2014-10-30 | Somahlution, Llc | Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life |
| US20160088832A1 (en) * | 2013-04-29 | 2016-03-31 | Somahlution, Llc | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution |
| CA2923441C (en) | 2013-11-22 | 2023-03-28 | Somahlution, Llc | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution |
| CN115720893B (zh) * | 2022-08-08 | 2024-02-23 | 四川大学华西医院 | 一种甲状旁腺体外保存液和保存方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4879283A (en) * | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
| ES2007994A6 (es) * | 1988-08-16 | 1989-07-01 | Grino Boira Jose Maria | Medio liquido para perfusion y preservacion de organos. |
| US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
| US4938961A (en) * | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
| US5104787A (en) * | 1990-03-05 | 1992-04-14 | Lindstrom Richard L | Method for apparatus for a defined serumfree medical solution useful for corneal preservation |
| US5145771A (en) * | 1990-04-12 | 1992-09-08 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
| GB9021325D0 (en) * | 1990-10-01 | 1990-11-14 | Geistlich Soehne Ag | Chemical composition |
| CH683485A5 (fr) * | 1990-11-20 | 1994-03-31 | Pasteur Merieux Serums Vacc | Solutions de perfusion, de conservation et de reperfusion d'organes. |
-
1993
- 1993-09-14 BE BE9300965A patent/BE1007500A3/fr not_active IP Right Cessation
- 1993-09-14 FR FR9310926A patent/FR2695827B1/fr not_active Expired - Lifetime
- 1993-09-14 CH CH02760/93A patent/CH686870A5/fr not_active IP Right Cessation
- 1993-09-15 CA CA002106249A patent/CA2106249C/fr not_active Expired - Lifetime
- 1993-09-16 IT ITMI931994A patent/IT1272638B/it active IP Right Grant
- 1993-09-17 ES ES09301971A patent/ES2070089B1/es not_active Expired - Fee Related
- 1993-09-17 GB GB9319264A patent/GB2270614B/en not_active Expired - Lifetime
- 1993-09-17 DE DE4331711A patent/DE4331711C2/de not_active Expired - Lifetime
- 1993-09-20 AT AT0189793A patent/AT407216B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2106249A1 (fr) | 1994-03-19 |
| GB2270614A (en) | 1994-03-23 |
| ATA189793A (de) | 2000-06-15 |
| CA2106249C (fr) | 2009-04-14 |
| GB2270614B (en) | 1996-03-20 |
| BE1007500A3 (fr) | 1995-07-18 |
| ITMI931994A0 (it) | 1993-09-16 |
| AT407216B (de) | 2001-01-25 |
| DE4331711C2 (de) | 2001-05-03 |
| ES2070089A1 (es) | 1995-05-16 |
| FR2695827B1 (fr) | 1995-07-28 |
| FR2695827A1 (fr) | 1994-03-25 |
| ITMI931994A1 (it) | 1995-03-16 |
| IT1272638B (it) | 1997-06-26 |
| ES2070089B1 (es) | 1995-12-16 |
| DE4331711A1 (de) | 1994-03-24 |
| GB9319264D0 (en) | 1993-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE1007500A3 (fr) | Solution de perfusion, de conservation et de reperfusion d'organes. | |
| US5498427A (en) | Solutions for the perfusion, preservation and reperfusion of organs | |
| US12213485B2 (en) | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops | |
| YTREHUS et al. | Influence of oxygen radicals generated by xanthine oxidase in the isolated perfused rat heart | |
| US5145771A (en) | Rinse solution for organs and tissues | |
| Taylor | Biology of cell survival in the cold: The basis for biopreservation of tissues and organs | |
| BE1006834A3 (fr) | Solution de perfusion, de conservation et de reperfusion d'organes. | |
| JP3326177B2 (ja) | 臓器保存液 | |
| FR2916606A1 (fr) | Procede de rincage et de conservation d'un organe en vue de sa transplantation et solution mise en oeuvre dans ce procede | |
| US9131677B2 (en) | Organ preservation solution | |
| US20120301866A1 (en) | Liquid formulation having dissolved gases useful for preserving biological material | |
| FR2632820A1 (fr) | Procede de conservation a basse temperature du sperme | |
| US8900804B2 (en) | Methods and solutions for tissue preservation | |
| KR100304594B1 (ko) | 이식용 장기 및 혈액세포 보존제의 조성물 | |
| FR3080002A1 (fr) | Procede de suivi de la viabilite d'un greffon | |
| Christie et al. | Lung preservation | |
| FR2679107A1 (fr) | Solutions de perfusion, de conservation et de reperfusion d'organes. | |
| WO2007043698A1 (ja) | 肝臓保存液 | |
| RU1561227C (ru) | Водный раствор для криоконсервирования тромбоцитов | |
| RU2049391C1 (ru) | Средство для криоконсервирования костного мозга | |
| Wicomb et al. | Loss of myocardial viability following hypothermic perfusion storage from contaminating trace elements in the perfusate | |
| FR2669189A1 (fr) | Solutions de perfusion et de stockage pour transplantations cardiaques. | |
| FR2723818A1 (fr) | Composition de perfusion pour ameliorer la conservation d'organes vivants | |
| Pristoupil et al. | Heart protection by cardioplegic solutions containing oxyhemoglobin pretreated by carbontetrachloride and freeze-drying with sucrose | |
| CA3015662C (en) | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUE | Assignment |
Owner name: PASTEUR MERIEUX SERUMS ET VACCINS TRANSFER- IMTIX- |
|
| PL | Patent ceased |